After many people reported problems with their pancreas post taking weight loss and diabetes injections, the UK health officials launched a study to look into side-effects of these drugs. Cases of pancreatitis, which causes inflammation of the pancreas, which is a gland located behind the stomach, has been fatal. These cases have been linked to GLP-1 medicines, also the glucagon-like peptide-1 receptor agonists. The Background The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is investigating a rise in reports of acute pancreatitis potentially linked to GLP-1 weight-loss medications. This follows an increase in submissions to the MHRA’s Yellow Card scheme, which tracks adverse reactions to medicines and medical devices.What Happens In Acute Pancreatitis?Acute pancreatitis is a sudden inflammation of the pancreas, a digestive gland behind the stomach, and often requires hospitalisation. Symptoms include intense abdominal pain, nausea, and fever. GLP-1 drugs, such as Mounjaro (tirzepatide), Wegovy and Ozempic (semaglutide), and liraglutide, list pancreatitis as an “uncommon” side effect—estimated to affect up to one in 100 users.To date, nearly 400 cases of acute pancreatitis have been reported in relation to these drugs, with 181 linked to Mounjaro. Alarmingly, over a quarter of those reports have emerged in 2025 alone. This year, the Yellow Card scheme has recorded 101 cases related to tirzepatide and 22 tied to semaglutide.What Did The Authorities Say?An MHRA spokesperson noted: “With increased usage, we’re seeing more Yellow Card reports involving GLP-1 medicines and acute pancreatitis.” While there’s currently no known genetic link, the MHRA is exploring whether genetics might influence susceptibility to such side effects. It has called on both patients and healthcare professionals to report suspected drug-related pancreatitis.The Study: Who Can Be Part Of It?Those affected may be invited to join the Yellow Card Biobank study, conducted with Genomics England. Participants will provide health information and saliva samples to help researchers investigate genetic factors that may affect drug reactions.Dr Alison Cave, MHRA’s chief safety officer, said nearly a third of all medicine side effects could be preventable with genetic testing, which may also help reduce the estimated £2.2 billion annual cost of adverse drug reactions to the NHS.Drug manufacturers have responded to the concerns. Eli Lilly, which makes Mounjaro, stated that patient safety remains a top priority and noted that pancreatitis is already listed as a known side effect. Novo Nordisk UK, maker of Ozempic and Wegovy, also stressed the importance of using GLP-1 medications only under medical supervision, while continuing to monitor safety data closely.The MHRA’s ongoing investigation aims to improve understanding of these side effects as GLP-1 medications become more widely used for managing obesity and diabetes.